Navigation Links
Isis Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference
Date:9/3/2014

CARLSBAD, Calif., Sept. 3, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Morgan Stanley Global Healthcare Conference on Monday, September 8, 2014 at 12:50 p.m. ET in New York, NY.

A live webcast of the presentation will be available on the "Investors & Media" section of the Company's website, www.isispharm.com.  A replay will be available on the Isis website within 48 hours and will be archived for a limited time.

About Isis Pharmaceuticals, Inc.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 32 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO®, in the United States and other countries for the treatment of patients with homozygous FH.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

Forward-Looking Statements
This press release includes forward-looking statements regarding Isis' business and the therapeutic potential of Isis' technologies and products in development.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2013, and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  KYNAMRO® is a registered trademark of Genzyme Corporation.

Logo - http://photos.prnewswire.com/prnh/20130807/LA60006LOGO


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. RXi Pharmaceuticals to Present at the Rodman & Renshaw 16th Annual Global Investment Conference
2. Edison Pharmaceuticals Announces Phase 2 Positive Clinical Results for EPI-743 in Rett Syndrome
3. Avanir Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference
4. VentiRx Pharmaceuticals Provides Corporate and Clinical Update
5. Arena Pharmaceuticals APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension
6. VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer
7. DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments
8. CAIDE Looks into the Future: New App from Merz Pharmaceuticals Assesses the Risk of Getting Dementia Within the Next 20 Years
9. Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytrens Cords At ASSH Annual Meeting
10. TWi Pharmaceuticals Receives US FDA Final Approval on Generic Megestrol Acetate 125mg/ml Oral Suspension
11. DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... 2016 As illustrated by the ... month, the numbers and momentum of cannabis in the ... the billions, more research and development push the sector ... of Legal Marijuana Markets Report  from from ArcView Market ... of the increase in sector is attributed to adult ...
(Date:5/25/2016)... , May 25, 2016 Digital ... issuance to it by the US Patent and ... company,s technology includes proprietary processes for electronic opt-­in ... health and wellness programs, HIPAA compliance and otherwise. ... "Our technology allows ...
(Date:5/25/2016)... England , May 25, 2016 ... company employing the precision of circulating tumour DNA ... today announces the appointment of Professor Clive ... provide medical leadership across the clinical development programme, ... Inivata,s products help deliver significant improvements in clinical ...
Breaking Medicine Technology:
(Date:5/27/2016)... York, NY (PRWEB) , ... May 27, 2016 ... ... care world, this installment is bolstered by inspiring human interest stories, courtesy of ... the developing trends and tech within the industry, from leading advocates and associations—namely ...
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media reports hinting ... and company to wait until March 2017 for an interest rate increase, according to ... College of Business. , “The Federal Open Market Committee (FOMC) dot charts are of ...
(Date:5/26/2016)... ... May 26, 2016 , ... Intalere, ... members and suppliers for its inaugural Member Conference at the Paris Hotel in ... elevating the operational health of America’s healthcare providers. , The conference was highlighted ...
(Date:5/26/2016)... Beach, Florida (PRWEB) , ... May 26, 2016 , ... ... Green House® Project offering a new model of care for living and healing, ... three core values: Meaningful Life in a Real Home provided by Empowered Staff. , ...
(Date:5/26/2016)... ... May 26, 2016 , ... Catalent Pharma Solutions, the ... consumer health and global clinical supply services, today announced two key appointments and ... continued investment and strategic growth plans in the Asia Pacific region. , Howard ...
Breaking Medicine News(10 mins):